Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma

Clinical Sarcoma Research

Richard Gorlick³  Douglas S Hawkins¹  Erin R Rudzinski⁵  Jonathan Gill⁴  David Geller²  Sajida Piperdi⁴  Michael Roth⁴  Vincent I Poon⁴ 

[1] Division of Pediatric Hematology/Oncology, Seattle Children’s Hospital, Fred Hutchinson Cancer Research Center, and University of Washington, Seattle, WA, USA;Department of Orthopaedic Surgery, Montefiore Medical Center and the Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA;Department of Pediatrics and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA;Division of Pediatric Hematology/Oncology, Children’s Hospital at Montefiore, Albert Einstein College of Medicine, 3415 Bainbridge Ave, Rosenthal Pavilion, Room 300, Bronx 10467, NY, USA;Department of Pathology, Seattle Children’s Hospital and University of Washington, Seattle, WA, USA

关键词: Antibody;    Immunotherapy;    Ganglioside GD2;    Osteosarcoma;   

Others  :  1092791
DOI  :  10.1186/s13569-014-0020-9

 received in 2014-11-13, accepted in 2014-12-19,  发布年份 2015

【 摘 要 】

Background

Osteosarcoma is the most common primary malignant bone tumor in children and young adults. Ganglioside GD2 has been previously found on the cell surface in various tumor types, including osteosarcomas.

Findings

In this study, forty-nine additional osteosarcoma samples from 14 individual patients were assessed for GD2 expression via immunohistochemistry, of which 47 samples were found to express GD2. In matched samples from patients, GD2 expression seen at initial biopsy was found to persist in 100% of tissues taken at recurrence.

Conclusions

GD2 expression was found to persist upon recurrence. These results suggest a phase 2 trial in children with recurrent osteosarcoma should provide an appropriate read out on the efficacy of anti-GD2 antibody.

【 授权许可】

   
2015 Poon et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al.: Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010, 363:1324-34.
• [2]Roth M, Linkowski M, Tarim J, Piperdi S, Sowers R, Geller D, et al.: Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer 2014, 120:548-54.
• [3]Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, et al.: Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 2014, 7:104-12.
• [4]Barsoum IB, Smallwood CA, Siemens DR, Graham CH: A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 2014, 74:665-74.
• [5]Anugraham M, Jacob F, Nixdorf S, Everest-Dass AV, Heinzelmann-Schwarz V, Packer NH: Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status. Mol Cell Proteomics 2014, 13(9):2213-32.
• [6]Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-8.
• [7]Iliopoulos D, Ernst C, Steplewski Z, Jambrosic JA, Rodeck U, Herlyn M, et al.: Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst 1989, 81:440-4.
• [8]Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K: Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res 2001, 61:4244-52.
• [9]Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, et al.: Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 2012, 122:2066-78.
• [10]Liang YJ, Ding Y, Levery SB, Lobaton M, Handa K, Hakomori SI: Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci U S A 2013, 110:4968-73.
• [11]Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK: Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Clin Cancer Res 1998, 4:2135-9.